Exploratory Study on the Efficacy of Betaine Hydrochloride in Treating Autoimmune Gastritis
In plain words A study of betaine HCl in people 18 to 80, run by Second Affiliated Hospital, Zhejiang University, School of Medicine. It plans to enroll about 100 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Autoimmune Gastritis.
- Patients diagnosed with autoimmune gastritis at the Second Affiliated Hospital of Zhejiang University School of Medicine, with the diagnostic criteria for autoimmune gastritis based on the article "A real-world study on the characteristics…
- Gastrin levels greater than 300 pmol/L or a history of type 1 gastric neuroendocrine tumors or early gastric cancer treated with endoscopic submucosal dissection (ESD);
- Age between 18 and 80 years;
- Patients who have signed the informed consent form for the clinical trial.
The exclusion criteria are on the listing.
What it tests, as registered
No intervention (Control Group); Oral betaine hydrochloride (2 capsules, 3 times daily)
Registered summary
Autoimmune gastritis (AIG) is a chronic autoimmune disorder characterized by parietal cell destruction and oxyntic mucosal atrophy, leading to achlorhydria and intrinsic factor deficiency. These pathological changes impair iron and vitamin B12 absorption, resulting in iron-deficiency anemia, pernicious anemia, and neuropsychiatric manifestations. Notably, 4-12% of AIG patients develop type 1 gastric neuroendocrine tumors, while facing a 3-7 fold increased risk of gastric adenocarcinoma with an incidence of 0.9-9%. The full summary is on the listing.
Where, as registered
No US site; China (1).